Abstract
Frontotemporal dementia is a disorder of paralimbic prefrontal-insular circuitry. The disorder is often sporadic but can be caused by genetic mutations in tau, progranulin, valosin, TDP-43 and CHMP2b. The major clinical manifestations of FTD include addictive behaviors, disinhibition, apathy, overeating and loss of sympathy and empathy for others. Treatment is currently focused around symptoms but disease-modifying therapies seem feasible.
Current Alzheimer Research
Title: Early Features in Frontotemporal Dementia
Volume: 6 Issue: 4
Author(s): Ana Maria Villamizar Caycedo, Bruce Miller, Joel Kramer and Katya Rascovsky
Affiliation:
Abstract: Frontotemporal dementia is a disorder of paralimbic prefrontal-insular circuitry. The disorder is often sporadic but can be caused by genetic mutations in tau, progranulin, valosin, TDP-43 and CHMP2b. The major clinical manifestations of FTD include addictive behaviors, disinhibition, apathy, overeating and loss of sympathy and empathy for others. Treatment is currently focused around symptoms but disease-modifying therapies seem feasible.
Export Options
About this article
Cite this article as:
Villamizar Caycedo Maria Ana, Miller Bruce, Kramer Joel and Rascovsky Katya, Early Features in Frontotemporal Dementia, Current Alzheimer Research 2009; 6 (4) . https://dx.doi.org/10.2174/156720509788929255
DOI https://dx.doi.org/10.2174/156720509788929255 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
Current Medicinal Chemistry Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology The Application of Minerals in Managing Alcohol Hangover: A Preliminary Review
Current Drug Abuse Reviews Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Editorial
Current Medical Imaging Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems
Current HIV Research Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer’s Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls
Current Alzheimer Research AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets S100b Induces Expression of Myoglobin in APβ Treated Neuronal Cells In Vitro: A Possible Neuroprotective Mechanism
Current Aging Science Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Familial Hypercholesterolemia: Etiology, Diagnosis and New Treatment Options
Current Pharmaceutical Design Application of Mesenchymal Stem Cells to Age-related Neuronal Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research